Biogen axes Denali-partnered Parkinson’s prospect after phase 2 flop

Biogen axes Denali-partnered Parkinson’s prospect after phase 2 flop is a pharma and life sciences industry update from FierceBiotech. The story may affect commercial strategy, market access planning, stakeholder engagement, competitive positioning, and near-term monitoring for pharmaceutical and biotech teams.

Nick Paul Taylor · 2026-05-22

A phase 2b trial of Biogen and Denali Therapeutics’ Parkinson’s disease candidate has missed its primary endpoint, prompting the partners to end development in the idiopathic form of the condition.

Source: FierceBiotech